• Aliases: ABT 199, GDC-0199, RG7601, SureCN523816, UNII-N54AIC43PW
    • An orally bioavailable, selective small-molecule inhibitor of the antiapoptotic protein BCL-2
    • FDA approved in April 2016 for patients with CLL who have 17p deletion chromosome
    • Dose: Escalation weekly up to 400 mg PO daily. Give on a fasting stomach (food will increase bioavailability of drug). Dose escalation to gradually debulk and reduce the risk of TLS. Consider antihyperuricemic therapy and hydration based on tumor lysis risk.
    • Half-life: â™26 hours
    • Side effects: Peripheral edema, nausea/diarrhea, fatigue, upper respiratory tract infection, cough, tumor lysis syndrome, neutropenia, thrombocytopenia
    Other topics in Targeted and Immunotherapy Agents